Combining Atorvastatin with Temozolomide for Glioblastoma Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of atorvastatin, a statin known for its cholesterol-lowering effects, when combined with temozolomide in treating glioblastoma, a highly aggressive brain tumor. The study aims to determine if this combination can improve patient outcomes, particularly given the poor prognosis associated with glioblastoma. Participants will be monitored for their response to treatment and any potential side effects. The trial focuses on patients diagnosed with IDH-wildtype glioblastoma, utilizing MRI scans for confirmation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. age ≥18 years old and \< 60 years old, both sexes;
2. sufficient evidence of glioma by MRI scan;
3. According to the 2021 WHO latest classification, the molecular pathology of postoperative glioma samples was diagnosed as WHO 4 glioblastoma;
4. The immunohistochemical results of postoperative glioma samples showed that EGFR score was 3 (standard: 0 was negative, 1-3 was positive);
5. normal blood routine and liver function;
6. fully understand the nature of the trial and sign the informed consent;
7. be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures;
8. no serious diseases or accidents requiring surgery;
9. normal immune function.

Exclusion Criteria:

1. allergy to atorvastatin or its components;
2. concomitant use of clarithromycin, itraconazole, ritonavir, saquinavir, lopinavir, cyclosporine, rifampicin, efavirenz, digoxin, warfarin, oral contraceptives;
3. other tumors (except glioma), hematological diseases or other known multiple organ failure, history of myasthenia gravis, heart failure, cerebral hernia and other serious complications;
4. History of cardiac insufficiency, arrhythmia, retinopathy, acute hepatic porphyrin, hepatic and renal insufficiency, obesity, uncontrolled diabetes and other metabolic diseases;
5. abnormal liver function or liver disease, including uncontrolled hepatitis;
6. other diseases that might interfere with the study, as determined by 2 attending neurosurgeons;
7. patients enrolled in a clinical trial within the past 4 weeks;
8. pregnant or lactating patients;
9. patients with poor compliance who could not complete the treatment;
10. other conditions that made the patient ineligible for enrollment as determined by the study investigator;
11. patients with a history of HIV and/or HBV/HCV or presence of HIV/HCV;
12. patients with a history of tuberculosis or known existence of tuberculosis;
13. patients with severe infection or signs/symptoms of infection within 2 weeks before the first dose of study drug;
14. patients who received live attenuated vaccine within 4 weeks before the first dose of study drug;
15. patients with previous solid organ transplantation or hematopoietic stem cell transplantation.

Those who meet any of the above criteria will not be selected.

Where it's running

• Tianjin Medical University General Hospital
  Tianjin, China Recruiting

Study contacts

• Principal investigator: Chunsheng Kang — Tianjin Medical University General Hospital
• Study coordinator: Chunsheng Kang
• Email: kang97061@tmu.edu.cn
• Phone: +8618622998838

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Temozolomide with or without WSD0922-FU for EGFR-Mutant, IDH-Wildtype Glioblastoma

  This trial tests whether adding WSD0922-FU to temozolomide helps slow disease progression in adults with EGFR-mutant, IDH-wildtype glioblastoma.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT07708961

• Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas

  This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07468136

• Temporally-Modulated Pulsed Radiation Therapy plus TMZ for MGMT-Unmethylated Glioblastoma

  This study tests whether temporally-modulated pulsed radiation therapy plus temozolomide improves outcomes for people with newly diagnosed MGMT-unmethylated, IDH-wildtype glioblastoma.

  Recruiting at 54 sites Phase 3 NRG Oncology · Irvine, California and 53 other locations · NCT07452458

• GI-102 With or Without Pembrolizumab Before Surgery for Recurrent or Progressive Grade 4 Gliomas

  The team will test whether giving GI-102 alone or together with pembrolizumab before surgery helps adults with recurrent or progressive IDH‑wildtype glioblastoma or IDH‑mutant grade 4 astrocytoma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07301268

• 177Lu-PSMA-617 treatment for IDH‑wildtype gliomas

  This trial will test whether the radiopharmaceutical 177Lu-PSMA-617 is safe for adults with IDH‑wildtype gliomas who have completed standard surgery and radiation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07223034

• Using a continuous glucose monitor to manage high blood sugar in glioblastoma

  We will try continuous glucose monitors to help adults with newly diagnosed glioblastoma control high blood sugar during treatment.

  Recruiting Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT07091864

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.